Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.

Aliment Pharmacol Ther

Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.

Published: November 2020

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.16113DOI Listing

Publication Analysis

Top Keywords

letter rationalising
4
rationalising aminosalicylates
4
aminosalicylates inflammatory
4
inflammatory bowel
4
bowel disease-authors'
4
disease-authors' reply
4
letter
1
aminosalicylates
1
inflammatory
1
bowel
1

Similar Publications

Article Synopsis
  • Platform trials are used in cancer research to test different treatments at the same time, making the process faster and more efficient.
  • The UK plasmaMATCH trial, which focused on advanced breast cancer, completed its main results within just 3 years by overcoming several challenges during its development.
  • Success in such trials relies on strong teamwork, clear planning, and good funding, ensuring everyone involved works well together.
View Article and Find Full Text PDF

Background: Drug-related deaths in the UK are at the highest level on record-the war on drugs has failed. A short film has been produced intended for public and professional audiences featuring academics, representatives of advocacy organisations, police and policymakers outlining the problems with, and highlighting alternative approaches to, UK drug policy. A range of ethical arguments are alluded to, which are distilled here in greater depth for interested viewers and a wider professional and academic readership.

View Article and Find Full Text PDF

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.

Med Hypotheses

November 2020

Chichuria Institute of Medical Science & Research, Thakurpara, Chichuria, Bethuadahari-II (XVI), Nadia, West Bengal 741 126, India. Electronic address:

It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), another two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.

View Article and Find Full Text PDF

Globally, there has been a measured response to rationalise elective operating during the Coronavirus disease 2019 (COVID-19) pandemic. In terms of breast cancer care, this has led to a restricted provision of reconstruction with autologous free tissue transfer. A primary concern is the risk of mortality in elective surgery patients who develop COVID-19.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!